Jazz Pharmaceuticals (JAZZ) Common Equity (2010 - 2026)

Jazz Pharmaceuticals' Common Equity history runs 17 years deep, the most recent figure standing at $4.5 billion for Q1 2026.

• In Q1 2026, Common Equity rose 8.56% year-over-year to $4.5 billion; the TTM figure through Mar 2026 stood at $4.5 billion (up 8.56% YoY), while the FY2025 annual figure was $4.3 billion, up 5.49% from the prior year.
• Common Equity was $4.5 billion for Q1 2026 at Jazz Pharmaceuticals, up from $4.3 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $4.5 billion in Q1 2026 to a low of $2.7 billion in Q3 2022.
• Historically, Common Equity has averaged $3.7 billion across 5 years, with a median of $3.7 billion in 2025.
• The sharpest annual moves came in 2022 and 2023: Common Equity plunged 30.3% in 2022, then climbed 27.11% in 2023.
• A 5-year view of Common Equity shows it stood at $3.1 billion in 2022, then climbed by 21.11% to $3.7 billion in 2023, then climbed by 9.55% to $4.1 billion in 2024, then increased by 5.49% to $4.3 billion in 2025, then advanced by 4.95% to $4.5 billion in 2026.
• The last three Common Equity figures came in at $4.5 billion (Q1 2026), $4.3 billion (Q4 2025), and $4.0 billion (Q3 2025), per Business Quant data.